News | CT Angiography (CTA) | April 05, 2016

One-Year PLATFORM Trial Results Reinforce Benefits of FFR-CT

A HeartFlow FFR-CT-guided strategy helps physicians avoid unnecessary invasive coronary diagnostics

FFR-CT, HeartFlow, PLATFORM trial, one-year results, ACC 2016

April 5, 2016 — Novel technology developed by HeartFlow Inc. significantly reduces the need for invasive procedures to diagnose patients suspected of having coronary artery disease. The HeartFlow FFR-CT (fractional flow reserve computed tomography) Analysis also leads to a sustained reduction in the cost of care, according to one-year data presented at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16).

The results were unveiled in a presentation on the multicenter, controlled, prospective PLATFORM (Prospective LongitudinAl Trial of FFR-CT: Outcome and Resource Impacts) trial, which compared standard diagnostic strategies to a HeartFlow-guided strategy in 584 patients with stable chest pain. The HeartFlow Analysis is the only non-invasive technology to provide physicians insight into both the extent of a patient’s arterial blockage and the functional impact the blockage has on blood flow.

Key findings of the presentation included that use of a HeartFlow-guided strategy resulted in the cancellation of a planned invasive coronary angiogram (ICA) in 60 percent of patients. After one year, none of the 117 patients who had ICA cancelled had suffered an adverse clinical event. Further, the data showed that use of a HeartFlow-guided strategy resulted in savings to the healthcare system of 33 percent after one year, as compared to patients who received standard care.

“The one-year data affirms use of the HeartFlow Analysis can in many patients safely eliminate the need for invasive catheterizations, and markedly reduce cost of care in patients with suspected coronary artery disease,” said lead investigator Pamela Douglas, M.D., the Ursula Geller Professor at the Duke Clinical Research Institute, Duke University School of Medicine. “This represents a significant advance in the diagnosis and treatment of patients with stable chest pain, who previously may have been sent for unnecessary invasive testing to determine appropriate treatment pathways.”

Studies have shown the need to improve the accuracy of non-invasive tests used to evaluate coronary artery disease. A recent study, which included data from more than 1,100 U.S. hospitals, found that 55 percent of the more than 385,000 patients with suspected coronary artery disease who underwent an ICA had no obstructive coronary disease. In the PLATFORM trial, a HeartFlow-guided strategy reduced the rate of normal or near-normal ICA by more than 80 percent.

The HeartFlow FFRCT Analysis is a Web-based platform that aids clinicians in diagnosing coronary artery disease, and provides personalized, actionable information to physicians to manage each patient. FFR-CT technology solves millions of complex equations simulating blood flow in the coronary arteries to provide mathematically computed fractional flow reserve values from images derived from non-invasive coronary CT angiography (cCTA). FFR-CT values indicate blood pressure differences around a coronary narrowing to determine whether it is likely to reduce blood flow to the heart.

The HeartFlow FFR-CT Analysis has been evaluated in four large, prospective clinical trials enrolling a total of more than 1,100 patients at major medical centers worldwide. It received CE mark in 2011 and U.S. Food and Drug Administration clearance in November 2014.

For more information: www.heartflow.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Chest CT findings of pediatric patients with COVID-19 on transaxial images. (a) Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe

Chest CT findings of pediatric patients with COVID-19 on transaxial images. Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe. Image courtesy of Radiology: Cardiothoracic Imaging

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Children and teenagers with COVID-19...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Sonogram taken under rib cage shows liver (grey) with curved diaphragm-lung border (white). Arrows point to vertical B lines (white) demonstrating diseased lung tissue. The more B lines the worse the disease. Healing is measured by reduction in the number of B lines.

Sonogram taken under rib cage shows liver (grey) with curved diaphragm-lung border (white). Arrows point to vertical B lines (white) demonstrating diseased lung tissue. The more B lines the worse the disease. Healing is measured by reduction in the number of B lines.

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Robert L.
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Feature | Radiation Dose Management | April 02, 2020 | By Melinda Taschetta-Millane
Rising concerns over...
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Updated CT scoring criteria from AJR considers both lobe involvement and changes in CT findings to quantitatively and accurately evaluate the progression of COVID-19 pneumonia

CT scoring criteria were applied to images from sequential chest CT examinations. A, Initial chest CT image obtained 2 days after onset of symptoms shows small region of subpleural ground-glass opacities in right lower lobe, for CT score of 1. B, Chest CT image obtained on day 3 of treatment shows slightly enlarged region of subpleural ground-glass opacities with partial crazy-paving pattern and consolidation, for CT score of 3. C, Chest CT image obtained on day 5 of treatment shows partial resolution of consolidation, for CT score of 2. D, Chest CT image obtained on day 14 of treatment shows continued resolution of consolidation with minimal residual ground-glass opacities, for CT score of 1. Image courtesy of American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 02, 2020
April 2, 2020 — Updated computed t...